Company news

Tectonic Therapeutic, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome

July 12, 2022

AVROBIO to Present at the H.C. Wainwright Global Investment Conference

May 15, 2022

AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update

May 9, 2022

AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting

May 2, 2022

AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update

March 16, 2022

AVROBIO to Present at Two Upcoming Investor Conferences in March

February 28, 2022

AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

January 31, 2022

AVROBIO to Present at Cowen’s 2nd Annual Genetic Medicines Summit

January 27, 2022

AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022

January 26, 2022

AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

November 23, 2021

AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference

November 7, 2021

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 4, 2021

AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome

November 2, 2021

AVROBIO Announces the Appointment of Essra Ridha, M.D., MRCP, FFPM, as Chief Medical Officer

October 25, 2021

AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress

October 5, 2021

← Newer news releases

Decks

The 5 newest of 13 decks. Every deck is listed under its year.